A Randomized Trial of Daily and Thrice-Weekly Trimethoprim-Sulfamethoxazole for the Prevention of Pneumocystis carinii Pneumonia in Human Immunodeficiency Virus-Infected Persons

We enrolled 2,625 human immunodeficiency virus-infected patients into a randomized trial to assess the efficacy and tolerability of daily vs. thrice-weekly trimethoprim-sulfamethoxazole (160 mg/800 mg) for prophylaxis of Pneumocystis carinii pneumonia (PCP). The rate of PCP was 3.5 and 4.1 per 100 p...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 1999-10, Vol.29 (4), p.775-783
Main Authors: El-Sadr, Wafaa M., Luskin-Hawk, Roberta, Yurik, Teresa McCabe, Walker, Janice, Abrams, Donald, John, Stanley L., Sherer, Renslow, Crane, Lawrence, Labriola, Ann, Caras, Susan, Pulling, Chris, Hafner, Richard
Format: Article
Language:English
Subjects:
AIDS
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial pneumonia
Biological and medical sciences
Clinical Articles
Dosage
HIV
Infectious diseases
Medical sciences
Medications
Pharmacology. Drug treatments
Pneumocystis pneumonia
Random allocation
Toxoplasmosis
Viruses
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We enrolled 2,625 human immunodeficiency virus-infected patients into a randomized trial to assess the efficacy and tolerability of daily vs. thrice-weekly trimethoprim-sulfamethoxazole (160 mg/800 mg) for prophylaxis of Pneumocystis carinii pneumonia (PCP). The rate of PCP was 3.5 and 4.1 per 100 person-years in the daily and thrice-weekly groups, respectively, with a relative risk (RR) of 0.82 (95% confidence interval [CI], 0.61-1.09; P = .16) (RR of
ISSN:1058-4838
1537-6591
DOI:10.1086/520433